P5. Evidence of Pdcd 4 as a novel marker for tumor diagnosis and progression in resected colorectal carcinomas  by Medved, F. et al.
28 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3P3. COMBINATION ANALYSIS OF ACTIVATOR PROTEIN-1
FAMILY MEMBERS, Sp1 AND AN ACTIVATOR PROTEIN-
2a-RELATED FACTOR BINDING TO DIFFERENT REGIONS OF
THE UROKINASE RECEPTOR (u-PAR) GENE IN RESECTED
COLORECTAL CANCERSDenis Martin Schewec, Tobias Billera, Gabriele Maurerd, Irfan A.
Asangania, Joerg H. Leupolda, Ernst R. Lengyele, Stefan Postb,
Heike Allgayera. aDepartment of Experimental Surgery and Molecular
Oncology, Universitaetsklinikum Mannheim, Germany; bDepartment of
Surgery Mannheim, University of Heidelberg, Heidelberg,
Germany; cDepartment of Pediatrics, Dr. v. Haunersches Kinderspital,
Germany; dKlinikum Grosshadern, Ludwig Maximilians University,
Munich, Germany; eDepartment of Obstetrics and Gynecology,
University of Chicago, Chicago, IL, United States.
Introduction: Studies on the transactivation of genes via pro-
moter elements have mostly been done on cell lines rather than
resected tissues. This, however, is essential to address an
in vivo or clinical relevance. We have previously shown tumor-
specific binding of Sp1and an activator protein (AP)-2a related fac-
tor to promoter region -152/-135 of the metastasis-related u-PAR
gene in 60% of in vivo resected cancer tissues. Cell lines have
implicated an additional role, and potential synergism, of an
AP-1 region (-190/-171) in u-PAR regulation. This study was done
to (a) analyze AP-1 binding to this region in resected tumor and
normal tissues, and define subgroups in which it is tumor-spe-
cific, and (b) to analyze transcription factor binding patterns to
both promoter motifs in resected tissues, supporting synergism,
and draw first prognostic conclusions.
Methods: In 103 patients with colorectal cancer, electrophoretic
mobility shift assay/supershift analysis for u-PAR promoter
region -190/-171 was done in tumors and normal tissues. In 71
patients, region -152/-135 was also analyzed. U-PAR protein was
measured by ELISA.
Results: Tumor-specific AP-1 binding to region -190/-171 of the u-
PAR promoter was found in 40% of patients. Subgroup analysis
showed tumor-specific binding for c-Fos in 58%, for c-Jun in
50%, for JunD in 39%, and for Fra-1 in 4% of cases. AP-1 binding
correlated significantly with u-PAR protein amounts in both nor-
mal and tumor tissues (p < 0.001), in contrast to a tumor-specific
correlation with u-PAR of the AP-2/Sp1 region. In analyses for
both promoter regions, 62% of cancers showed simultaneous
binding for AP-1, AP-2, and Sp1, 11% for AP-1 and AP-2, 16% for
AP-2 and Sp1, 4% for AP-2 only, 3% for AP-1 only, and 0% for
Sp1 only. The binding of AP-1, AP-2, and Sp1 correlated signifi-
cantly with each other (p < 0.001), the combination of AP-1 and
AP-2 showing the highest correlation with u-PAR (p = 0.008). Preli-
minary survival analysis indicated a trend for poorer prognosis
for binding of all three transcription factors.
Conclusion: This is the first study differentiating transcription
factor binding to two important u-PAR promoter regions in a large
series of resected tumors and normal tissues. The AP-1 site seems
to be a less tumor-specific regulator than the Sp1/AP-2 motif.
Nevertheless, data corroborate the hypothesis of synergism
between both elements in resected tumors.
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Background: Tumor-suppressor Pdcd4 has never been investi-
gated as to a potential role in invasion/metastasis. The urokinase
receptor (u-PAR) promotes invasion and metastasis and is associ-
ated with a poor cancer-patient survival. The present study was
conducted: (1) to implicate a role of Pdcd4 in invasion and u-
PAR-regulation, (2) to describe first mechanisms by which this is
achieved.
Methods: Diverse gastrointestinal carcinoma cell lines were
screened for Pdcd4- and u-PAR expression and protein amounts
by Northern-, Western blot analysis respectively RT-PCR. To deter-
mine a potential regulation of the u-PAR promoter by Pdcd4, CAT-
and luciferase reporter assays using diverse u-PAR wildtype and
deletions mutants were undertaken and potential cis-element
were screened for transcription factor binding by EMSA. Invasion
and intravasation influenced by Pdcd4 were tested by using differ-
ent invasion assay approaches.
Results: In colon/gastric cancer cell lines, a reciprocal expression
of u-PAR and Pdcd4 was observed. RKO and HCT116 colon cancer
cells made to express Pdcd4 showed a reduction in u-PAR-mRNA
and -protein, this being paralleled by an inhibition of invasion/
intravasation. A CAT-reporter driven by the wildtype u-PAR-pro-
moter was reduced in constitutive activity with increasing
Pdcd4-expression. Deletion of a region containing a putative
Sp-1 binding site at -402/-350 inhibited u-PAR-promoter regula-
tion by Pdcd4, this being paralleled by a reduction of Sp1 binding
to this region in pdcd4-transfected cells. Pdcd4-transfected
cells showed an increase of Sp3 binding to u-PAR-promoter region
-152/-135, and the deletion of this region reduced the ability of
Pdcd4 to suppress u-PAR-promoter activity.
Conclusion: These data suggest Pdcd4 as a new negative regula-
tor of invasion and the invasion-related gene u-PAR. Furthermore,
it is the first study to implicate Pdcd4-induced gene expression
via Sp3 induction and Sp1 suppression.
doi:10.1016/j.ejcsup.2006.04.064
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potential tumor suppressor, expression of which is downregu-
lated in various human tumor types. Additionally, Pdcd4 is able
to inhibit the neoplastic transformation in the JB6 mouse model.
Pdcd4 has been shown to inhibit translation of diverse regula-
tory factors important for neoplastic transformation. Moreover,
it was shown that AKT phosphorylates Pdcd4, causing nuclear
translocation and inactivation of the latter. This suggests that
Pdcd4 activity is dependent on its cellular localisation. Up to
now, Pdcd4 protein expression and cellular localisation has not
been analysed in a large series of patients with colorectal cancer
(CRC).
Methods: We investigated the expression pattern and localisa-
tion of Pdcd4 tumor suppressor protein in resected tumor and
corresponding normal tissue in a series of 41 CRC patients (32
R0-resected) who did not receive neoadjuvant treatment, by Wes-
tern blotting (WB) and immunhistochemistry (IHC). A separate
semiquantitative score for ICH staining of the cytoplasm and
nuclei was established. Preliminary analysis of Pdcd4 expression
and localisation was correlated with patient’s clinical tumor stage
(UICC) and with recurrence-free survival.
Results: In WB high overall Pdcd4 amounts were detected in nor-
mal tissue in comparison to the tumor samples where the signal
was significantly decreased (p = 0.025, Wilcoxon). IHC analysis
revealed strong nuclear presence of Pdcd4 in the apical cryptal
epithelium of normal tissue, as opposed to the complete loss of
nuclear expression in tumor tissue (p = 0.001, Wilcoxon). In nor-
mal tissue, loss of Pdcd4 nuclear expression/increase of cytoplas-
mic Pdcd4-staining was significantly associated with advanced
UICC stages (p = 0.027, v2). Preliminary Kaplan–Meier-analysis
(median recurrence-free survival time: 38 months, range: 1–74
months) showed a trend for loss of Pdcd4 expression in the nuclei
of the normal tissue to be associated with poor recurrence-free
survival (p = 0.09, Breslow log rank).
Conclusion: This is the first clinical study that demonstrates a
potential relevance of Pdcd4 expression and localisation in
resected colorectal tumors and corresponding normal tissue, for
tumor diagnosis and progression. Further analysis of colorectal
adenomas will be performed to study the role of Pdcd4 localisa-
tion as a potential clinical marker for carcinogenesis in CRC.
doi:10.1016/j.ejcsup.2006.04.065
P6. PROTEINASES ACTIVATED RECEPTORS: EXPRESSION
AND QUANTIFICATION IN COLON AND PROSTATE
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University Hospital, Cre´teil, France.Background: Proteinases activated receptors (PARs) are impor-
tant members of the G protein-coupled receptors family. The
proteolytic cleavage of their extracellular domain by serine pro-
teases such as trypsin or thrombin, generates an autoactivating
tethered-ligand. Thus, the corresponding activated G proteins
trigger a cascade of downstream events leading to diverse cellu-
lar outcomes such as calcium signalling, cell adhesion, cell
migration and mitogenesis. The role of proteases in promoting
invasion of cancer cells and tumorigenesis have prompted us
to study the expression level and localisation of the four known
members of the PARs family and explore their role in cell
proliferation.
Methods: First, by using quantitative RT-PCR, we have quanti-
fied: (i) the expression of each PAR in colon and prostate cancer
cell lines, (ii) the PARs expression in 40 patients samples (colon
or prostate normal tissue and cancer). Second, we have studied
PARs tissue localisation in colon and prostate, by using immuno-
histochemistry staining on TMA samples. Finally, we investigated
the role of the four members of PAR family (PAR1-4) in cell prolif-
eration by stimulating cell lines in different conditions (various
thrombin concentrations).
Results: Our results show that the expression profile of the PARs
is different for each PAR and depend mostly of the cell lines char-
acterisation (origin and stage). However, we demonstrate a con-
stant overexpression of two PARs in every tested cell line, that
was also found in tumor samples.
Immunohistochemichal analysis shows PAR1 endothelial
expression which was stronger in malignant tissues (prostate
and colon samples), and weaker (prostate) or absent (colon) in
normal tissues.
Conclusion: These results confirm the importance of PARs in
cancer, whose expression pattern is likely to influence cancer cell
behaviour in tumors.
doi:10.1016/j.ejcsup.2006.04.066
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Background: Glioblastomas are the most common malignant
brain tumors in adults characterized by very aggressive local growth
and invasiveness. Tumor invasion into surrounding brain tissue is
facilitated by increased expression and activity of matrix metallo-
proteinases (MMPs), which may be marker for tumor aggressive-
ness. However, for several of the 23 human MMPs there are no or
only very limited literature data available concerning expression
by glioblastomas. Therefore, we screened an extensive panel of 15
low-grade astrocytomas and 15 glioblastomas in order to fill the
gaps in our knowledge about MMP expression by these tumors.
Methods: Expression of MMPs was analysed by semiquantitative
RT-PCR and immunostaining. Total RNA was used as template for
RT-PCR. Immunostaining was performed on cryosections.
